Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04215523 · ClinicalTrials.gov registry record
Replication of the DECLARE Diabetes Trial in Healthcare Claims
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 49,790
- Enrollment target
NCT04215523: Completed study, sponsored by Brigham and Women's Hospital.
NCT04215523 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 49,790 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04215523 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 49,790 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Composite outcome of MI, stroke, and mortality - Please refer to uploaded protocol for full definition due to size limitations.
Interventions
- DRUG Dapagliflozin
- DRUG DPP-4 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49,790 participants |
| Start Date | 2019-07-08 |
| Est. Completion | 2021-02-18 |
What the finished NCT04215523 record still lists
NCT04215523 is an observational study that tracks outcomes without assigning an intervention. Its 49,790 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT04215523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04215523 about?
NCT04215523 is a clinical study titled "Replication of the DECLARE Diabetes Trial in Healthcare Claims". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT04215523?
This trial is currently completed. The enrollment target is 49,790 participants. The study started on 2019-07-08. Estimated completion is 2021-02-18.
What interventions are being tested in trial NCT04215523?
The interventions under investigation include: Dapagliflozin (DRUG), DPP-4 inhibitor (DRUG).
Who is sponsoring clinical trial NCT04215523?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
- NCT01885299 · 50,000 participants
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
- NCT03452774 · 50,000 participants
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- NCT04629586 · 50,000 participants
The T1D Exchange Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI